Hypertension linked to PDE3A activation

Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains

(2015) Graeme B. Bolger et al.   CELLULAR SIGNALLING

PDE3A mutations cause autosomal dominant hypertension with brachydactyly

(2015) Philipp G Maass et al.   NATURE GENETICS

Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases

(2014) Katharine H. Abbott-Banner et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis

(2014) Tadashi Kaname et al.   CELLULAR SIGNALLING

Association between phosphodiesterase 4D polymorphism SNP83 and ischemic stroke

(2013) Yan Yan et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Platelet Antiaggregants in Stroke Prevention

(2013) Sarkis G. Morales Vidal et al.   NEUROLOGIC CLINICS

Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms

(2013) F. Vandeput et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

(2009) PH Schafer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

(2009) Alex B Burgin et al.   NATURE BIOTECHNOLOGY

Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown

(2009) Miles D. Houslay   TRENDS IN BIOCHEMICAL SCIENCES